Tilray Beats Earnings, But Investors Still Selling Off

Tilray Brands (TLRY) delivered a strong earnings beat, surpassing expectations and reporting a 97.2% improvement in earnings per share. The company narrowed its loss to $0.24 per share, compared to a $8.69 per share loss in the prior-year quarter. Tilray also reaffirmed its 2026 adjusted EBITDA guidance and highlighted international cannabis growth and strategic partnerships as key growth drivers.

Revenue

Tilray Brands reported total revenue of $206.73 million in fiscal 2026 Q3, marking an 11.3% increase from $185.78 million in the same period last year. The company's beverage segment generated $42.56 million in revenue, while the cannabis segment reached $64.83 million. The distribution business led all segments with $82.96 million, and the wellness segment contributed $16.38 million to the overall net revenue. This balanced performance across multiple segments underscores the company’s strategic diversification and operational strength.

Earnings/Net Income

Tilray Brands significantly reduced its net loss in Q3 2026, reporting a loss of $25.23 million, a 96.8% improvement from the $793.53 million loss in the prior-year quarter. The earnings per share (EPS) loss also dropped dramatically to $0.24 from $8.69, reflecting a 97.2% year-over-year improvement. These results demonstrate a strong turnaround and highlight the company’s progress in cost discipline and operational efficiency. The narrowing of the loss is a positive sign for investors.

Post-Earnings Price Action Review

Following the release of its Q3 2026 earnings report, Tilray Brands (TLRY) experienced a mixed response in the market. While the stock initially surged by 8.01% due to the earnings beat, it has since seen a downward trend. The stock price dropped 7.11% during the latest trading day, tumbled 11.53% over the course of the most recent full trading week, and has plummeted 19.21% month-to-date. This volatility highlights investor uncertainty despite the company’s strong earnings performance. Market reactions appear to be influenced by broader industry dynamics and lingering concerns about the U.S. cannabis regulatory landscape, which remain key factors in investor sentiment.

CEO Commentary

Irwin Simon, Chairman and CEO of Tilray Brands, emphasized the company’s record Q3 revenue of $207 million, driven by 11% organic growth and international cannabis expansion, including 73% year-over-year growth. He highlighted the BrewDog acquisition, which elevated Tilray to a $1.2 billion global revenue platform, and strategic partnerships with Carlsberg to strengthen beverage scale. Challenges such as U.S. cannabis regulatory uncertainty and price compression in international markets were acknowledged. Simon also underlined progress in AI-driven cannabis cultivation and cost discipline via Project Four Twenty, which led to 32% beverage gross margins. He expressed optimism about vertical integration in Germany, leveraging CC Pharma’s distribution, and long-term growth in medical cannabis, wellness, and international markets.

Guidance

Tilray Brands reaffirmed its fiscal 2026 adjusted EBITDA guidance of $62–72 million. The CEO expects continued international cannabis growth, sequential beverage margin improvements, and operational leverage from Carlsberg and BrewDog partnerships. Forward-looking priorities include navigating U.S. cannabis rescheduling, scaling AI-driven cannabis production, and expanding into new markets like the Middle East and Asia-Pacific. The company maintains a $3.5 million net cash position to fund strategic opportunities.

Additional News

In recent weeks, Tilray Brands has made several strategic moves that have drawn attention. On March 19, 2026, the company announced a major expansion of its medical cannabis portfolio in Australia, the largest such initiative in its history. This move aims to meet surging demand in the regulated market and expand local offerings through established prescribers, pharmacies, and clinical distribution channels. On March 26, 2026, Tilray announced a partnership with The Magnum Ice Cream Company to sell Popsicle-branded ready-to-drink alcoholic beverages in the United States. This includes the launch of Popsicle Hard beverages with 5% ABV in three non-carbonated flavors, set for a statewide release in March 2026 at major retailers such as Walmart, Kroger, and Safeway. These initiatives reflect Tilray’s strategic focus on diversification and market expansion.